Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY) and MannKind (MNKD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Surgery Partners (SGRY – Research Report) and MannKind (MNKD – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Surgery Partners (SGRY)
In a report released today, A.J. Rice from UBS maintained a Buy rating on Surgery Partners, with a price target of $21.00. The company’s shares closed last Wednesday at $14.08.
According to TipRanks.com, Rice is a 5-star analyst with an average return of
Currently, the analyst consensus on Surgery Partners is a Strong Buy with an average price target of $21.06, which is a 52.2% upside from current levels. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $33.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
MannKind (MNKD)
In a report released today, Yun Zhong from Wedbush assigned a Buy rating to MannKind, with a price target of $8.00. The company’s shares closed last Wednesday at $2.95.
According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $7.25 average price target, implying a 144.9% upside from current levels. In a report issued on February 25, Leerink Partners also maintained a Buy rating on the stock.
